Libby Sousa

Libby Sousa is an associate in Goodwin’s Life Sciences group. Libby’s representation of private and public companies spans the entire corporate life cycle, including startup and formation matters, venture capital financings, mergers and acquisitions, initial public offerings, follow-on offerings, strategic investments, and other capital markets transactions. Libby also represents publicly traded biotechnology companies in SEC reporting, securities law compliance, and corporate governance matters. Libby joined Goodwin in 2022.

Capital Market Transactions

• Aura Biosceinces, Inc., in its $75 million follow-on offering
• Century Therapeutics, in its $135 million private placement financing
• Palvella Therapeutics, Inc., in its $230 million public offering
• Altimmune, Inc., in its $225 million follow-on offering and $75 million registered direct offering
• Akero Therapeutics, Inc., in its $402.5 million follow-on offering

Venture Capital Financings and Mergers and Acquisitions

• City Therapeutics, Inc., in its $99 million Series B financing
• Actithera, Inc., in its oversubscribed $75.5 million Series A financing
• Represented a private therapeutics company in its $15.2 million Series A financing and subsequent $8.5 million extension
• Represented a private therapeutics company in its $45 million Series A financing
• Third Arc Bio, Inc., in its oversubscribed $165 million Series A financing and $52.66 million Series A financing extension
• Represented a private company in its acquisition of certain assets for $30 million in a combination of cash and milestone payments
• Represented a private company in its acquisition of certain assets for $11 million in upfront cash and future milestone consideration
• Represented a private biopharmaceutical company in connection with an option and stock purchase agreement pursuant to which a major pharmaceutical company was granted an exclusive option to acquire all of the outstanding capital stock of the company for an upfront payment of $30 million, with stockholders entitled to an additional option exercise price of $157.5 million plus aggregate milestone payments of up to $332.5 million upon exercise

Prior to law school, Libby worked at Marsh & McLennan as a casualty broker specializing in product liability for life sciences companies.

• Author, “Debunking the Standardized Nature of Insurance Policies,” Fordham Journal of Corporate & Financial Law, October 5, 2022 
• Co-Author, “Insurtech Innovation in the Metaverse,” Goodwin Insights, January 5, 2023